[go: up one dir, main page]

AU3834295A - Wet granulation formulation for a piperazinylcamphorsulfonyl oxytocin receptor antagonist - Google Patents

Wet granulation formulation for a piperazinylcamphorsulfonyl oxytocin receptor antagonist

Info

Publication number
AU3834295A
AU3834295A AU38342/95A AU3834295A AU3834295A AU 3834295 A AU3834295 A AU 3834295A AU 38342/95 A AU38342/95 A AU 38342/95A AU 3834295 A AU3834295 A AU 3834295A AU 3834295 A AU3834295 A AU 3834295A
Authority
AU
Australia
Prior art keywords
piperazinylcamphorsulfonyl
receptor antagonist
wet granulation
oxytocin receptor
granulation formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38342/95A
Inventor
Mandana Asgharnejad
David E. Storey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU3834295A publication Critical patent/AU3834295A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
AU38342/95A 1994-10-20 1995-10-16 Wet granulation formulation for a piperazinylcamphorsulfonyl oxytocin receptor antagonist Abandoned AU3834295A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32641894A 1994-10-20 1994-10-20
PCT/US1995/013342 WO1996012476A1 (en) 1994-10-20 1995-10-16 Wet granulation formulation for a piperazinylcamphorsulfonyl oxytocin receptor antagonist
US326418 2002-12-23

Publications (1)

Publication Number Publication Date
AU3834295A true AU3834295A (en) 1996-05-15

Family

ID=23272115

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38342/95A Abandoned AU3834295A (en) 1994-10-20 1995-10-16 Wet granulation formulation for a piperazinylcamphorsulfonyl oxytocin receptor antagonist

Country Status (2)

Country Link
AU (1) AU3834295A (en)
WO (1) WO1996012476A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US5073380A (en) * 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
SK28794A3 (en) * 1991-09-13 1995-07-11 Merck & Co Inc Piperazinyl(sulfonyl) amide derivatives of camphor as oxytocin antagonists
HRP940163A2 (en) * 1993-03-12 1996-08-31 Merck & Co Inc Process to derivatives of piperizinylcamphorsulfonyl oxytocin antagonists

Also Published As

Publication number Publication date
WO1996012476A1 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
AU7079498A (en) Neuropeptide y receptor antagonist
AU1251597A (en) Cosmetic composition containing a neuropeptide Y receptor antagonist
AU3503797A (en) Fibrinogen receptor antagonist prodrugs
AU7692996A (en) Receptor antagonists
AU3953795A (en) Bicyclic neuropeptide y receptor antagonists
AU2242197A (en) Benzimidzolyl neuropeptide y receptor antagonists
AU2290695A (en) Offset job separator
AU2169097A (en) Automatically braking device when leaving a protected area
AU1698997A (en) Tocolytic oxytocin receptor antagonists
AU3234395A (en) Glycine receptor antagonist pharmacophore
AU9185598A (en) Novel neuropeptide y receptor antagonists
AU4763896A (en) Tocolytic oxytocin receptor antagonists
AU5026599A (en) A wet granulation method for preparing a stable pharmaceutical formulation
AU1715099A (en) Memory protection system for a multi-tasking system
AU3503397A (en) Fibrinogen receptor antagonist prodrugs
AU1311495A (en) Flooring for a farrowing pen
AU5158798A (en) Protection system for a wood chip destructuring device
AU6230698A (en) Dopamine d4 receptor antagonist
AU3356795A (en) A device for a scaffold
EP1023295A4 (en) Fibrinogen receptor antagonist prodrugs
AU3834295A (en) Wet granulation formulation for a piperazinylcamphorsulfonyl oxytocin receptor antagonist
AU6979494A (en) Azacyclic-heterocyclic compounds as angiotensin ii receptor antagonists
AU8798298A (en) A feeding device
AU6916098A (en) A device for indicating direction
AU6826498A (en) Endotholin receptor antagonists